Pharvaris Statistics
Total Valuation
Pharvaris has a market cap or net worth of $1.86 billion. The enterprise value is $1.51 billion.
Important Dates
The next estimated earnings date is Tuesday, May 12, 2026, after market close.
| Earnings Date | May 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Pharvaris has 64.96 million shares outstanding. The number of shares has increased by 9.65% in one year.
| Current Share Class | 64.96M |
| Shares Outstanding | 64.96M |
| Shares Change (YoY) | +9.65% |
| Shares Change (QoQ) | +13.84% |
| Owned by Insiders (%) | 3.42% |
| Owned by Institutions (%) | 53.66% |
| Float | 34.66M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 5.84 |
| P/TBV Ratio | 5.82 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.11, with a Debt / Equity ratio of 0.00.
| Current Ratio | 10.11 |
| Quick Ratio | 10.01 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -43.67 |
Financial Efficiency
Return on equity (ROE) is -65.19% and return on invested capital (ROIC) is -39.26%.
| Return on Equity (ROE) | -65.19% |
| Return on Assets (ROA) | -35.81% |
| Return on Invested Capital (ROIC) | -39.26% |
| Return on Capital Employed (ROCE) | -62.47% |
| Weighted Average Cost of Capital (WACC) | -9.74% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.75M |
| Employee Count | 118 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Pharvaris has paid $2.33 million in taxes.
| Income Tax | 2.33M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +91.57% in the last 52 weeks. The beta is -2.58, so Pharvaris's price volatility has been lower than the market average.
| Beta (5Y) | -2.58 |
| 52-Week Price Change | +91.57% |
| 50-Day Moving Average | 27.07 |
| 200-Day Moving Average | 24.02 |
| Relative Strength Index (RSI) | 59.00 |
| Average Volume (20 Days) | 201,742 |
Short Selling Information
The latest short interest is 740,455, so 1.14% of the outstanding shares have been sold short.
| Short Interest | 740,455 |
| Short Previous Month | 751,905 |
| Short % of Shares Out | 1.14% |
| Short % of Float | 2.14% |
| Short Ratio (days to cover) | 5.96 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -199.39M |
| Pretax Income | -203.96M |
| Net Income | -206.29M |
| EBITDA | -198.90M |
| EBIT | -199.39M |
| Earnings Per Share (EPS) | -$3.49 |
Full Income StatementBalance Sheet
The company has $342.47 million in cash and $912,056 in debt, with a net cash position of $341.55 million or $5.26 per share.
| Cash & Cash Equivalents | 342.47M |
| Total Debt | 912,056 |
| Net Cash | 341.55M |
| Net Cash Per Share | $5.26 |
| Equity (Book Value) | 318.51M |
| Book Value Per Share | 4.89 |
| Working Capital | 316.50M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$160.94 million and capital expenditures -$193,283, giving a free cash flow of -$155.12 million.
| Operating Cash Flow | -160.94M |
| Capital Expenditures | -193,283 |
| Depreciation & Amortization | 64,717 |
| Net Borrowing | -206,913 |
| Free Cash Flow | -155.12M |
| FCF Per Share | -$2.39 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Pharvaris does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.65% |
| Shareholder Yield | -9.65% |
| Earnings Yield | -11.12% |
| FCF Yield | -8.36% |
Analyst Forecast
The average price target for Pharvaris is $40.70, which is 43.26% higher than the current price. The consensus rating is "Buy".
| Price Target | $40.70 |
| Price Target Difference | 43.26% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
